Galapagos NV
http://www.glpg.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Galapagos NV
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Biotechs Vie To Take The Lead In Autoimmune CAR-Ts
First clinical efficacy readouts from several biotech companies developing CAR-Ts for systemic lupus erythematosus will be unveiled at EULAR, though the level of competition may be unsustainable.
Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program
Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 16th annual Deals of the Year contest. We've selected 12 nominees across three categories – Top M&A, Top Alliance and Top Financing – and you get to pick the winners.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
- Large Molecule
- Other Names / Subsidiaries
-
- Abound Bio, Inc.
- CellPoint B.V.
- Discovery Partners International
- Inpharmatica Ltd.
- Sareum Holdings plc.
- ProSkelia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice